AVDL 财务： Avadel Pharmaceuticals PLC AI 分析

主页

股票

AVDL

AVDL 财务

Avadel Pharmaceuticals PLC

$21.64

收盘价：Feb 13, 16:00:00 GMT-5

$21.64

盘后：Feb 13, 20:00:00 GMT-5

概述预测收益股息财务数据

收入

资产负债表

现金流量

年度

季度性

AVDL 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
营收	248	169	27	0	0	22
营收同比增长 (YoY)	80%	526%	--	--	-100%	-63%
营收成本	22	15	0	--	0	5
毛利润	226	153	27	--	0	16
销售、一般及管理费用	191	181	151	74	68	32
研发	39	15	13	20	17	20
营业费用	231	196	164	95	85	56
其他非经营性收入 (费用)	1	4	0	0	2	2
税前利润	-3	-49	-160	-111	-93	-5
所得税费用	-2	0	0	26	-15	-2
净利润	0	-48	-160	-137	-77	7
净利润增长	-100%	-70%	17%	78%	-1,200%	-121%
稀释后流通股数	101.27	95.14	80.17	60.09	58.53	54.94
股份同比变动 (YoY)	5%	19%	33%	3%	7%	47%
每股收益 (摊薄)	0	-0.51	-2	-2.29	-1.32	0.12
每股收益增长率	-99%	-74%	-13%	73%	-1,200%	-112.99%
自由现金流	19	-46	-128	-71	-77	-48
每股自由现金流	--	--	--	--	--	--
毛利率	91.12%	90.53%	100%	--	0%	72.72%
营业利润率	-1.61%	-24.85%	-507.4%	0%	0%	-177.27%
净利率	0%	-28.4%	-592.59%	0%	0%	31.81%
自由现金流利润率	7.66%	-27.21%	-474.07%	0%	0%	-218.18%
EBITDA	-1	-40	-136	-94	-85	-39
EBITDA 利润率	-0.4%	-23.66%	-503.7%	0%	0%	-177.27%
EBITDA 中的折旧与摊销	3	2	1	1	0	0
EBIT	-4	-42	-137	-95	-85	-39
EBIT 利润率	-1.61%	-24.85%	-507.4%	0%	0%	-177.27%
有效税率	66.66%	0%	0%	-23.42%	16.12%	40%

关键数据

前收盘价

$21.64

开盘价

$21.64

当日区间

$21.64 - $21.64

52周范围

$6.38 - $23.57

交易量

35.0M

平均成交量

2.0M

每股收益（TTM）

-0.01

股息收益率

市值

$1.9B

什么是 AVDL？

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 188 full-time employees. The firm's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

功能特性

资源